|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.7 TWD | -0.39% |
|
+0.40% | -13.04% |
Li Kang Biomedical Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 684.25 million compared to TWD 386.97 million a year ago. Net income was TWD 112.09 million compared to TWD 51.44 million a year ago.
Basic earnings per share from continuing operations was TWD 4.1826 compared to TWD 1.9217 a year ago. Diluted earnings per share from continuing operations was TWD 4.1565 compared to TWD 1.913 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.04% | 49.93M | |
| +15.92% | 8.35B | |
| +3.37% | 7.62B | |
| +1.49% | 6.01B | |
| -5.33% | 3.75B | |
| -7.57% | 3.7B | |
| -2.94% | 1.34B | |
| -26.08% | 1.13B | |
| +14.95% | 992M | |
| -9.40% | 925M |
LI KANG BIOMEDICAL CO., LTD. 
